KENYA – The Pharmacy and Poisons Board of Kenya has issued a public alert regarding counterfeit Ozempic Pens (Semaglutide) that have been falsely labeled and are circulating in the market.
This alert follows a warning from INTERPOL about the falsification of these diabetes treatment devices, which has raised significant concerns about public health safety.
The board clarified that the Ozempic Pens, intended for managing type 1 and type 2 diabetes, are not registered or authorized for sale in Kenya.
“Any product marketed as Ozempic Pens is illegal, and the Board cannot ascertain their safety, quality, and effectiveness,” the statement emphasized.
This means that consumers may unknowingly purchase products that do not meet health standards, posing severe risks to their health.
The counterfeit products in question are Apidra Solostar pens (glulisine), which are legitimate diabetes medications but have been misbranded to appear as Ozempic Pens.
The board’s rapid response initiative aims to investigate and verify whether these falsified products are currently available in the Kenyan market.
“To safeguard public safety, the Board has initiated a rapid response and heightened surveillance to verify whether the falsified Ozempic (Semaglutide) Pens are presently circulating in the Kenyan market,” the board stated.
In light of this situation, the Pharmacy and Poisons Board has urged the public and healthcare professionals to refrain from purchasing, distributing, or administering these counterfeit pens.
“The Board cautions the public and healthcare professionals against trading, distributing, wholesaling, retailing, issuing, dispensing, using, or administering the falsified Ozempic (Semaglutide) Pens, as such actions are illegal and jeopardize public health and safety,” the statement warned.
The board also encourages individuals to report suspicious activities or products related to Ozempic Pens.
They have provided several reporting channels, including their official website, a mobile application available on Android and iOS, a USSD code, and a dedicated email address.
“We encourage the public and healthcare professionals to immediately share any information regarding Ozempic Pens with the Pharmacy and Poisons Board,” the board urged.
This alert is critical as the demand for diabetes medications continues to rise. The board’s proactive measures reflect its commitment to protecting public health and ensuring that only safe and effective medications are available in the market.
Dr. F. M. Siyoi, the Chief Executive Officer of the Pharmacy and Poisons Board, has reiterated the importance of vigilance among consumers and healthcare providers.
“The public must remain alert and report any suspected cases of sub-standard or falsified health products,” he stated.
As the situation develops, the board will continue to monitor the market and take necessary actions to safeguard Kenyans’ health.
The public is urged to stay informed and cautious when purchasing medications, especially those not recognized or approved by health authorities.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE
